Alumis ALMS
NASDAQ ALMS
$7.75 -0.02 (-0.26%)
As of: Sep 21, 2026 · 2:52 PM EDT

Alumis (ALMS) Income towards Parent Company (2023 - 2026)

Alumis' (ALMS) quarterly Income towards Parent Company came in at -$142.2 million in Q2 2026, down 339.52% year-over-year from $59.4 million in Q2 2025, and down 192.34% quarter-over-quarter from -$48.6 million in Q4 2025.

Analysis

Alumis (ALMS) Income towards Parent Company (2023 - 2026) Analysis & Trends

Alumis (ALMS) has reported Income towards Parent Company for 4 consecutive years, with -$142.2 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Income towards Parent Company fell 339.52% year-over-year to -$142.2 million in Q2 2026; TTM through Jun 2026 was -$242.2 million, a 43.95% decrease from a year earlier, with the FY2025 full-year figure at -$199.0 million, up 14.39% from the prior year.
  • Income towards Parent Company was -$142.2 million for Q2 2026 at Alumis, down from -$48.6 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $59.4 million in Q2 2025 and troughed at -$142.2 million in Q2 2026.
  • A 4-year average of -$57.9 million and a median of -$48.1 million in 2024 frame the typical range for Income towards Parent Company.
  • Across the five-year window, Income towards Parent Company surged 205.05% in 2025 and sank 339.52% in 2026, its largest moves.
  • Over 4 years, Income towards Parent Company stood at -$40.1 million in 2023, then increased by 17.85% to -$33.0 million in 2024, then slumped by 47.51% to -$48.6 million in 2025, then sank by 192.34% to -$142.2 million in 2026.
  • The last three Income towards Parent Company figures came in at -$142.2 million (Q2 2026), -$48.6 million (Q4 2025), and -$110.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn
10 Alumis 966.94 Mn 464.65 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -142.18 Mn
Dec 31, 2025 -48.64 Mn
Sep 30, 2025 -110.75 Mn
Jun 30, 2025 59.36 Mn
Mar 31, 2025 -101.53 Mn
Dec 31, 2024 -32.97 Mn
Sep 30, 2024 -93.12 Mn
Jun 30, 2024 -56.51 Mn
Mar 31, 2024 -47.59 Mn
Dec 31, 2023 -40.13 Mn
Sep 30, 2023 -43.76 Mn
Jun 30, 2023 -36.71 Mn
API Access

Alumis Income towards Parent Company API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-towards-parent-company&ticker=ALMS&period=max&api_key=YOUR_API_KEY